Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis
Authors' conclusion
In this nested case-control study of patients with SLE and RA, we found a reduced risk of overall CV events associated with current HCQ use, including reductions in VTE and trends toward reductions in MI and stroke.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in inception cohorts, entire population of British Columbia, Canada10,268 cases and 29,969 controls
- Comparison
- Current, recent and never hydroxychloroquine (HCQ) use vs remote HCQ use
- Outcome
- Incident cardiovascular (CV) events:
- Myocardial infarction (MI)
- Stroke
- Venous thromboembolism (VTE)
Methodological detailsinception cohorts of SLE and RA, population-based administrative health databases, matched on age, sex and rheumatic disease (up to 3 controls per case), conditional logistic regression
- Inception cohorts of SLE and RA
- Population-based administrative health databases
- Matched on age, sex and rheumatic disease (up to 3 controls per case)
- Conditional logistic regression
Main finding
As reported in the abstract
Combined CV events
Adjusted cOR
0.86
95% CI 0.77–0.97
Current use
cOR
0.93
95% CI 0.77–1.13
Recent use
cOR
0.96
95% CI 0.88–1.04
Never used
Observational data: associations, not effects.
Further findings
| Outcome | Adjusted cOR (95% CI) |
|---|---|
| MICurrent use vs Remote use | 0.88 (0.74–1.05) |
| StrokeCurrent use vs Remote use | 0.87 (0.74–1.03) |
| VTECurrent use vs Remote use | 0.74 (0.59–0.94) |
Original publication
Hydroxychloroquine Use and Cardiovascular Events Among Patients With Systemic Lupus Erythematosus and Rheumatoid Arthritis. Arthritis Care Res (Hoboken). Published 17 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →